Ashraf Badros, MD
Medical Oncology · Baltimore, MDNPI 1821038241
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,020 of the $22,916 with a category attached, or 69.9%. 19 manufacturers reported payments, led by Sanofi at 52.4% of the total. Reporting peaked in 2024 at $10,683 and has fallen 87.4% since, to $1,342 in 2025.
Across 54 payments — averaging $424.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$12K
- Amgen$8K
- E.r. Squibb & Sons, L.L.C.$1K
- Janssen Research & Development, LLC$783
- Janssen Scientific Affairs, LLC$599
- Pharmacyclics LLC, An Abbvie Company$156
- plus $756 from 13 others
Across 323 payments — averaging $22,254 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$2.3M
- GSK$1.8M
- Janssen Research & Development, LLC$1.1M
- Bristol Myers Squibb$1.1M
- Genentech, Inc.$322K
- Pfizer$318K
- plus $180K from 5 others
What the payments were for
- Consulting fees$16,02070%
- Grants$2,0399%
- Travel & lodging$3,10014%
- Food & beverage$1,7578%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 5 | $12,009 |
| Amgen | 10 | $7,589 |
| E.r. Squibb & Sons, L.L.C. | 2 | $1,023 |
| Janssen Research & Development, LLC | 6 | $783 |
| Janssen Scientific Affairs, LLC | 2 | $599 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $156 |
| Pfizer | 5 | $115 |
| Beigene USA, Inc. | 1 | $109 |
| Legend Biotech USA Inc. | 3 | $104 |
| Merck | 3 | $81 |
| GSK | 2 | $70 |
| Daiichi Sankyo Inc. | 2 | $59 |
| F. Hoffmann-la Roche AG | 1 | $49 |
| Johnson & Johnson | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $36 |
| Bristol Myers Squibb | 1 | $25 |
| Syndax Pharmaceuticals, Inc. | 1 | $25 |
| Tersera Therapeutics LLC | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,916 in reported general payments places this provider in the 70th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 88 | $2,044,933 |
| RevlimidLenalidomide | 55 | $979,953 |
| Acyclovir | 18 | $335 |
| Ondansetron Hcl | 12 | $234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,023 | $2,044,93388 claims |
| Bristol Myers SquibbRevlimid | $25 | $979,95355 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 180 medical oncology providers in Maryland.
Other medical oncology in Baltimore
- Mario EisenbergerBaltimore$2.9M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Mark LevisBaltimore$323K
- Tanguy Lim-SeiwertBaltimore$301K
- Shruti ChaturvediBaltimore$265K
- Sandy KotiahBaltimore$247K
- Bruce SmithBaltimore$235K
- Evan LipsonBaltimore$228K
- Nilofer AzadBaltimore$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.